1-10 of 10
Melanie Janning
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase Ib/II Study (NCT02488408 / BGBC003) of Bemcentinib Monotherapy or in Combination with Cytarabine or Decitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS): FINAL Results

Sonja Loges, Michael Heuser, Jolanta Chromik, Grerk Sutamtewagul, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto Massimo Lemoli, Daniele Giovanni Mattei, Isabel Ben Batalla, Jonas Waizenegger, Melanie Janning, Lisa-Marie Rieckmann, Charles Imbusch, Niklas Beumer, David Micklam, Claudia Gorcea-Carson, Cristina Oliva, Walter Fiedler, Yesid Alvarado-Valero, Nigel McCracken, Bjorn T. Gjertsen
Journal: Blood
Blood (2023) 142 (Supplement 1): 4287.
https://doi.org/10.1182/blood-2023-181833
Published: 2023
Journal Articles

AML Treatment By the AXL Inhibitor Bemcentinib in Combination with Cytarabine Shows Clinical Efficacy Related to TNFα and Cytotoxic Immune Cells: A Single-Cell Translational Study from the BGBC003 Trial

Niklas Beumer, Jonas S. Waizenegger, Michael Heuser, Jörg Chromik, Grerk Sutamtewagul, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele G. Mattei, Walter Fiedler, Yesid Alvarado-Valero, David Micklem, Linn H. Nilsson, Noelly Madeleine, Nigel McCracken, Cristina Oliva, Claudia Gorcea-Carson, Lisa-Marie Rieckmann, Jenny Krause, Victoria Gensch, Isabel Ben Batalla, Melanie Janning, Nicola Gagliani, Benedikt Brors, Charles D. Imbusch, Bjorn T. Gjertsen, Sonja Loges
Journal: Blood
Blood (2023) 142 (Supplement 1): 1540.
https://doi.org/10.1182/blood-2023-185499
Published: 2023
Journal Articles

Bemcentinib (Oral AXL Inhibitor) in Combination with Low-Dose Cytarabine Is Well Tolerated and Efficacious in Older Relapsed AML Patients.Updates from the Ongoing Phase II Trial (NCT02488408) and Preliminary Translational Results Indicating Bemcentinib Elicits Anti-AML Immune Responses

Sonja Loges, Grerk Sutamtewagul, Michael Heuser, Jörg Chromik, Silke Kapp-Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele Giovanni Mattei, Isabel Ben Batalla, Monica Hellesøy, Jonas Waizenegger, Melanie Janning, Charles D. Imbusch, Niklas Beumer, Austin Rayford, Jaya Nautiyal, Tzivia Berkman-Gottlieb, David Micklem, Hani Gabra, Claudia Gorcea-Carson, James B. Lorens, Walter Fiedler, Yesid Alvarado, Bjorn T. Gjertsen, Lisa-Marie Rieckmann
Journal: Blood
Blood (2021) 138 (Supplement 1): 3410.
https://doi.org/10.1182/blood-2021-147225
Published: 2021
Journal Articles

Molecular Response Patterns in Relapsed/Refractory AML Patients Treated with Selinexor and Chemotherapy

Piroska Klement, Walter Fiedler, Razif Gabdoulline, Louisa-Kristin Dallmann, Clara Wienecke, Johannes Schiller, Christian Kandziora, Katrin Teich, Bennet Heida, Maximilian Brandes, Carolin Funke, Martin Wichmann, Basem Othman, Jörg Chromik, Konstantin Büttner, Stefanie Amberg, Maxim Kebenko, Vera Schlipfenbacher, Anne C Wilke, Franziska Modemann, Melanie Janning, Hubert Serve, Carsten Bokemeyer, Ute Deppermann, Anne L. Kranich, Arnold Ganser, Felicitas Thol, Michael Heuser
Journal: Blood
Blood (2021) 138 (Supplement 1): 2369.
https://doi.org/10.1182/blood-2021-151091
Published: 2021
Journal Articles

Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS

Sonja Loges, MD, PhD, Michael Heuser, MD, Joerg Chromik, Carlos E Vigil, MD, Peter Paschka, MD, Isabel Ben-Batalla, PhD, Nuray Akyüz, David Micklem, Robert Holt, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD, Bjorn Gjertsen, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2672.
https://doi.org/10.1182/blood-2018-99-120380
Published: 2018
Journal Articles

The Orally Available Selective Axl Inhibitor BGB324 Induces Diversification of the Immune Repertoire and Specific Changes in Plasma Biomarker Profiles

Sonja Loges, MD PhD, Bjørn Tore Gjertsen, Michael Heuser, MD, Joerg Chromik, Isabel Ben-Batalla, Nuray Akyüz, David Micklem, Anthony Brown, James Lorens, Murray Yule, Maxim Kebenko, MD, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1375.
https://doi.org/10.1182/blood.V130.Suppl_1.1375.1375
Published: 2017
Journal Articles

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Juergen Krauter, MD, Walter Fiedler, MD, Richard F. Schlenk, MD, Peter Paschka, MD, Felicitas Thol, MD, Michael Lübbert, MD, Mohammad Amen Wattad, MD, Mareike Verbeek, Christian Koenecke, MD, Barbara Neuhaus, Maxim Kebenko, Melanie Janning, Konstanze Dohner, MD, Verena I. Gaidzik, MD, Heiko Becker, MD, Christine Greil, MD, Peter Reimer, MD, Katharina Götze, MD, Hartmut Döhner, MD, Arnold Ganser, MD, Michael Heuser, MD
Journal: Blood
Blood (2016) 128 (22): 4038.
https://doi.org/10.1182/blood.V128.22.4038.4038
Published: 2016
Journal Articles

BGB324, an Orally Available Selective Axl Inhibitor Exerts Anti-Leukemic Activity in the First-in-Patient Trial BGBC003 and Induces Unique Changes in Biomarker Profiles

Loges Sonja, Bjorn T. Gjertsen, Michael Heuser, Jörg Chromik, Isabel Ben Batalla, Nuray Akyüz, PhD, David Micklem, Anthony Brown, Jim Lorens, Maxim Kebenko, Melanie Janning, Mascha Binder, MD, Walter Fiedler, MD, Jorge E. Cortes, MD
Journal: Blood
Blood (2016) 128 (22): 592.
https://doi.org/10.1182/blood.V128.22.592.592
Published: 2016
Journal Articles

BGB324 Represents an Axl and BCR-ABL1 Inhibitor with Activity in the T315I Mutant

Robert Erdmann, PhDMSc, Heather Jorgensen, PhD, Isabel Ben-Batalla, PhD, Nils Kruse, PhD, David Micklem, PhD, Gunhild von Amsberg, MD, Philippe Schafhausen, MD, Alexander Schultze, MD MSc, Mark Wroblewski, MSc, Mascha Binder, Miguel Cubas-Cordova, MSc, Tobias Hadlich, MD, Melanie Janning, MD MSc, Stefanie Sawall, Victoria Gensch, Elaine K Allan, Leena Mukherjee, PhD, Heather Morrison, BSc, Jennifer Cassells, Nicolaus Kroeger, MD, James Lorens, MD, Richard E. Clark, MD, Steffen Koschmieder, MD, Peter Vandenberghe, MD PhD, Tim H. Brümmendorf, MD, Andreas Hochhaus, MD, Peter Carmeliet, MD PhD, Tessa L. Holyoake, MD PhD, Klaus Pantel, MD PhD, Carsten Bokemeyer, MD, Sonja Loges, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4512.
https://doi.org/10.1182/blood.V124.21.4512.4512
Published: 2014
Journal Articles

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma

Isabel Ben-Batalla, Alexander Schultze, Mark Wroblewski, Robert Erdmann, Michael Heuser, Jonas S. Waizenegger, Kristoffer Riecken, Mascha Binder, Denis Schewe, Stefanie Sawall, Victoria Witzke, Miguel Cubas-Cordova, Melanie Janning, Jasmin Wellbrock, Boris Fehse, Christian Hagel, Jürgen Krauter, Arnold Ganser, James B. Lorens, Walter Fiedler, Peter Carmeliet, Klaus Pantel, Carsten Bokemeyer, Sonja Loges
Journal: Blood
Blood (2013) 122 (14): 2443–2452.
https://doi.org/10.1182/blood-2013-03-491431
Published: 2013
Includes: Supplemental data